Literature DB >> 12482227

Fatal ergotism induced by an HIV protease inhibitor.

Marc A Tribble, Clark R Gregg, David M Margolis, Robin Amirkhan, James W Smith.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12482227     DOI: 10.1046/j.1526-4610.2002.02163.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


× No keyword cloud information.
  7 in total

1.  Risk of stroke, gangrene from ergot drug interactions.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2003-04-15       Impact factor: 8.262

2.  Ergotism: Case Report and Review of the Literature.

Authors:  Claudia A Liegl; Michael A McGrath
Journal:  Int J Angiol       Date:  2015-02-09

Review 3.  [Epidemiology and therapy of pain and depression during HIV and AIDS].

Authors:  I W Husstedt; D Reichelt; F Kästner; S Evers; K Hahn
Journal:  Schmerz       Date:  2009-12       Impact factor: 1.107

Review 4.  Medical causes of headache in children.

Authors:  Nicholas S Abend; Donald Younkin
Journal:  Curr Pain Headache Rep       Date:  2007-10

Review 5.  Genetics, genomics and evolution of ergot alkaloid diversity.

Authors:  Carolyn A Young; Christopher L Schardl; Daniel G Panaccione; Simona Florea; Johanna E Takach; Nikki D Charlton; Neil Moore; Jennifer S Webb; Jolanta Jaromczyk
Journal:  Toxins (Basel)       Date:  2015-04-14       Impact factor: 4.546

Review 6.  Cabergoline: a review of its use in the inhibition of lactation for women living with HIV.

Authors:  Karen J Tulloch; Philippe Dodin; Fannie Tremblay-Racine; Chelsea Elwood; Deborah Money; Isabelle Boucoiran
Journal:  J Int AIDS Soc       Date:  2019-06       Impact factor: 5.396

7.  Use of lopinavir/ritonavir associated with ergotamine resulting in foot amputation: brief communication.

Authors:  Fernando Raphael de Almeida Ferry; Guilherme Almeida Rosa Da Silva; Rogerio Neves Motta; Ricardo de Souza Carvalho; Carlos Alberto Morais De Sá
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 May-Jun       Impact factor: 1.846

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.